Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1α expression in peripheral blood mononuclear cells

Molecular Medicine Reports

Volumn 13, Issue 1, 2016, Pages 35-40

  Jiang, Ya ^a   Wang, Lin ^b  

^a Hefei Third People's Hospital   (China)

^b WANNAN MEDICAL COLLEGE   (China)

Author keywords

Ankylosing spondylitis; Histone deactylase 3; MicroRNA 130a; Peripheral blood mononuclear cells; Tumor necrosis factor 1

Indexed keywords

HISTONE DEACETYLASE 3; MICRORNA; MICRORNA 130A; MICRORNA 15A; MICRORNA 16 1; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR 1 ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; MESSENGER RNA; MIRN130 MICRORNA, HUMAN; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MOLECULAR PATHOLOGY; NEGATIVE FEEDBACK; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RNA INTERFERENCE; UPREGULATION; FEEDBACK SYSTEM; GENETICS; METABOLISM; MONONUCLEAR CELL;

FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HUMANS; LEUKOCYTES, MONONUCLEAR; MICRORNAS; RNA, MESSENGER; RNA, SMALL INTERFERING; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954228604     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4494     Document Type: Article

References (29)

1. Kim N, Sun HY, Youn MY and Yoo JY: IL-1β-specific recruitment of GCN5 histone acetyltransferase induces the release of PAF1 from chromatin for the de-repression of inflammatory response genes. Nucleic Acids Res 41: 4495-4506, 2013.
2. Grabiec AM, Tak PP and Reedquist KA: Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: Should we keep our HATs on? Arthritis Res Ther 10: 226, 2008.
3. Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R, Zhang Y, Rembold M, Gaisberger M, Hartl A, et al: Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol 185: 3489-3497, 2010.
4. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, Miconnet I, et al: Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 117: 1205-1217, 2011.
5. Katto J, Engel N, Abbas W, Herbein G and Mahlknecht U: Transcription factor NFkB regulates the expression of the histone deacetylase SIRT1. Clin Epigenetics 5: 11, 2013.
6. Blanchard F and Chipoy C: Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Discov Today 10: 197-204, 2005.
7. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT and Kim DY: Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 35: 89-96, 2005.
8. Toussirot E, Wendling D, Herbein G and CIC-1431: Biological treatments given in patients with rheumatoid arthritis or ankylosing spondylitis modify HAT/HDAC (histone acetyltransferase/histone deacetylase) balance. Joint Bone Spine 81: 544-545, 2014.
9. Gillespie J, Savic S, Wong C, Hempshall A, Inman M, Emery P, Grigg R and McDermott MF: Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 64: 418-422, 2012.
10. Strietholt S, Maurer B, Peters MA, Pap T and Gay S: Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther 10: 219, 2008.
11. Yang CR, Shih KS, Liou JP, Wu YW, Hsieh IN, Lee HY, Lin TC and Wang JH: Denbinobin upregulates miR-146a expression and attenuates IL-1β-induced upregulation of ICAM-1 and VCAM-1 expressions in osteoarthritis fibroblast-like synoviocytes. J Mol Med (Berl) 2014 [Epub ahead of print].
12. Lu MC, Yu CL, Chen HC, Yu HC, Huang HB and Lai NS: Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1. Mediated interleukin-10 production. Clin Exp Immunol 177: 641-651, 2014.
13. Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Minisola G, et al: miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol 71: 206-211, 2010.
14. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH and Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10: R101, 2008.
15. Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y, Liang D, He D, Wang H, Liu W, et al: The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat Med 18: 1077-1086, 2012.
16. Lai NS, Yu HC, Chen HC, Yu CL, Huang HB and Lu MC: Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis. Clin Exp Immunol 173: 47-57, 2013.
17. Meng S, Cao J, Zhang X, Fan Y, Fang L, Wang C, Lv Z, Fu D and Li Y: Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3. PloS One 8: e68611, 2013.
18. Li S, Duan X, Li Y, Liu B, McGilvray I and Chen L: MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat 21: 121-128, 2014.
19. Osbourne A, Calway T, Broman M, McSharry S, Earley J and Kim GH: Downregulation of connexin43 by microRNA-130a in cardiomyocytes results in cardiac arrhythmias. J Mol Cell Cardiol 74: 53-63, 2014.
20. Kim GH, Samant SA, Earley JU and Svensson EC: Translational control of FOG-2 expression in cardiomyocytes by microRNA-130a. PloS One 4: e6161, 2009.
21. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E and Tao J: Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 31: 3002-3008, 2012.
22. Kim Y, Kim H, Park H, Park D, Lee H, Lee YS, Choe J, Kim YM and Jeoung D: miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem 289: 28019-28039, 2014.
23. Zhang J, Kalkum M, Chait BT and Roeder RG: The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell 9: 611-623, 2002.
24. Bendinelli P, Matteucci E, Maroni P and Desiderio MA: NF-kappaB activation, dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells. Mol Cancer Res 7: 1328-1341, 2009.
25. Mahlknecht U, Will J, Varin A, Hoelzer D and Herbein G: Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol 173: 3979-3990, 2004.
26. Han KA, Kang HS, Lee JW, Yoo L, Im E, Hong A, Lee YJ, Shin WH and Chung KC: Histone deacetylase 3 Promotes RCAN1 Stability and nuclear translocation. PloS One 9: e105416, 2014.
27. Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, Manganelli S and Galeazzi M: Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. 2014: 862969, 2014.
28. Fenix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, Puigventós-Latorre F, Borrero-Rubio JM and López-Vallejo JF: Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 38: 286-293, 2013.
29. Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L and Scarpa R: Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33: 833-839, 2014.